First Preclinical Development Candidate for Nucleome Therapeutics - Takeaways - MDSpire

First Preclinical Development Candidate for Nucleome Therapeutics

First-in-class monoclonal antibody agonist program for inflammation

  • January 19, 2026

  • 2 min

Share

  • 1

    Nucleome Therapeutics has nominated NTP464 as its first preclinical development candidate for inflammation resolution.

  • 2

    NTP464 is a monoclonal antibody agonist targeting a novel inflammation checkpoint linked to autoimmune diseases.

  • 3

    The company's Micro Capture-C platform enables high-resolution mapping of genome interactions to aid drug discovery.

  • 4

    NTP464 has shown strong potency in preclinical tests by inhibiting immune cell activation and enhancing regulatory T cell activity.

  • 5

    The program will advance to IND-enabling studies, focusing on treating conditions like rheumatoid arthritis and lupus.

Original Source(s)

First Preclinical Development Candidate for Nucleome Therapeutics

  • January 19, 2026

Related Content

Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential

After the Appendix Is Gone

A long-term pediatric cohort study raises new questions about gut immunity following appendectomy.

Medical Oddities: Essential Oil, Deadly Consequences

A cabinet mix-up, a chatty heart, a violet catheter bag, stressed kids, and tea that won’t save the brain—just another week.